• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Section 32 Raises $740 Million Venture Fund

    11/4/21 8:14:00 AM ET
    $COIN
    $CRWD
    $EXAS
    $RLAY
    Finance: Consumer Services
    Finance
    Computer Software: Prepackaged Software
    Technology
    Get the next $COIN alert in real time by email

    SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

    Section 32 is a venture capital fund investing at the frontiers of technology and healthcare.

    "I'm so pleased that Nina has joined this team and I look forward to what this growing group will achieve together," commented Bill Maris, founder of Section 32. "What a privilege it is to close this fourth fund, and to thus have the continued opportunity to try to use capital as a lever to accelerate the profound positive impact technology can have on healthcare and humanity."

    The closing of Fund 4 brings assets under management for Section 32 to over $1.8B. To-date, Section 32 has made investments in more than 70 companies including Coinbase (NASDAQ:COIN), Crowdstrike (NASDAQ:CRWD), Relay Therapeutics (NASDAQ:RLAY), Thrive Earlier Detection (NASDAQ:EXAS), and Vir Biotechnology (NASDAQ:VIR). Section 32 has made eight investments from Fund 4 following an initial close of the fund in July 2021.

    Since its inception in 2017, Section 32 has grown to 16 people, including four managing partners: Bill Maris, Michael Pellini, M.D., Steve Kafka, Ph.D., and Andy Harrison, with offices in San Diego, Silicon Valley and Boston, MA. The team's cumulative career experience includes contributing to more than 130 company exits (through acquisition or public offerings) and helping to build and finance more than 50 companies with valuations in excess of $1 billion.

    With the closing of Fund 4, Section 32 added Nina Labatt to its team as its chief operating officer and chief financial officer. Nina brings more than two decades of experience to her new role and is recognized as an industry expert leading finance and operations in venture capital and private equity.

    "I'm delighted to join the team at Section 32 at this exciting time in the firm's growth," commented Nina Labatt. "I look forward to collaborating with the team to continue building world-class operations and finance functions that support our investing efforts."

    Most recently, Nina served as chief operating officer and general partner at Trinity Ventures, where she managed finance, marketing, data analytics, human resources, and legal for the firm. She also led internal strategic initiatives, structured and executed investment transactions with the investing team and participated in the firm's fundraising efforts. Previously, Ms. Labatt served as managing director, Private Equity Services for Silicon Valley Bank, as well as chief financial officer for Health Evolution Partners. Earlier in her career, Ms. Labatt was an investment banker for Goldman Sachs and Montgomery Securities. Ms. Labatt received a bachelor's degree in economics and a master's degree in international policy studies from Stanford University. She received her MBA from Harvard Business School. She was a founding member of the Northern California board of directors for the CFO Leadership Council and previously served as chairperson of the board of directors of VCBC, a non-profit association for finance professionals in venture capital.

    About Section 32

    Section 32 is a venture capital fund investing at the frontiers of technology and healthcare. Founded by Bill Maris, the team has vast experience building iconic companies. The firm's goal is to improve the human condition by accelerating the discovery, development and distribution of important technologies and life-saving medicines. Section 32 invests across the entirety of technology and life sciences. This includes software, cybersecurity, advanced communications and computation, space, climate change related technologies, machine learning, artificial intelligence, biotechnology, therapeutics, advanced diagnostics, precision medicine, genomics and more. For more information, please visit Section32.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/section-32-raises-740-million-venture-fund-301416494.html

    SOURCE Section 32

    Get the next $COIN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COIN
    $CRWD
    $EXAS
    $RLAY

    CompanyDatePrice TargetRatingAnalyst
    Coinbase Global Inc.
    $COIN
    11/20/2025Buy → Hold
    Erste Group
    CrowdStrike Holdings Inc.
    $CRWD
    11/18/2025$600.00Hold
    Berenberg
    Coinbase Global Inc.
    $COIN
    11/10/2025$375.00Neutral → Buy
    Monness Crespi & Hardt
    Coinbase Global Inc.
    $COIN
    10/30/2025$425.00Sell → Buy
    H.C. Wainwright
    CrowdStrike Holdings Inc.
    $CRWD
    10/28/2025$706.00Neutral → Buy
    Arete
    Coinbase Global Inc.
    $COIN
    10/24/2025$404.00Neutral → Overweight
    Analyst
    Coinbase Global Inc.
    $COIN
    10/3/2025$417.00Neutral → Buy
    Rothschild & Co Redburn
    Coinbase Global Inc.
    $COIN
    10/1/2025$410.00Buy
    BTIG Research
    More analyst ratings

    $COIN
    $CRWD
    $EXAS
    $RLAY
    SEC Filings

    View All

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    11/21/25 6:56:03 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    11/20/25 5:23:44 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    11/20/25 4:56:30 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, GM, Screening Orville Jacob A sold $375,000 worth of shares (5,000 units at $75.00), decreasing direct ownership by 18% to 23,237 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/21/25 5:30:06 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SVP, General Counsel & Sec Herriott James sold $70,000 worth of shares (1,000 units at $70.00), decreasing direct ownership by 8% to 11,585 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/21/25 5:30:03 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Chief Financial Officer Haas Alesia J sold $1,983,554 worth of shares (7,242 units at $273.90), decreasing direct ownership by 6% to 79,320 units (SEC Form 4)

    4 - Coinbase Global, Inc. (0001679788) (Issuer)

    11/19/25 4:30:29 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coinbase Global downgraded by Erste Group

    Erste Group downgraded Coinbase Global from Buy to Hold

    11/20/25 8:40:33 AM ET
    $COIN
    Finance: Consumer Services
    Finance

    Berenberg initiated coverage on CrowdStrike with a new price target

    Berenberg initiated coverage of CrowdStrike with a rating of Hold and set a new price target of $600.00

    11/18/25 8:21:50 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    Coinbase Global upgraded by Monness Crespi & Hardt with a new price target

    Monness Crespi & Hardt upgraded Coinbase Global from Neutral to Buy and set a new price target of $375.00

    11/10/25 8:33:52 AM ET
    $COIN
    Finance: Consumer Services
    Finance

    President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/13/24 12:56:28 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    CrowdStrike to Participate in Upcoming Investor Conference

    CrowdStrike Holdings, Inc. (NASDAQ:CRWD) today announced that it is scheduled to present at the following investor conference: UBS Global Technology and AI Conference Location: Scottsdale, AZ Date: Wednesday, December 3, 2025 Presentation Time: 7:35 a.m. MT The presentation will be webcast live and archived on CrowdStrike's investor relations website at ir.crowdstrike.com. About CrowdStrike Holdings CrowdStrike (NASDAQ:CRWD), a global cybersecurity leader, has redefined modern security with the world's most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data. Powered by the CrowdStrike Security Cloud an

    11/20/25 8:30:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    CrowdStrike Named One of the Top 25 Workplaces in the World in 2025

    98% of employees are proud to tell others they work at CrowdStrike CrowdStrike (NASDAQ:CRWD) today announced it has been named to Fortune World's Best Workplaces™ in 2025 by Great Place To Work® and Fortune magazine, recognizing CrowdStrike as one of only 25 companies worldwide honored for its exceptional culture and leadership. With 98% of employees proud to tell others they work at CrowdStrike, this recognition underscores the company's commitment to its mission, its people, and the innovation that leads cybersecurity in the AI era. "CrowdStrike is a mission-driven organization. What makes us special is our people and our purpose," said J.C. Herrera, chief human resources officer at C

    11/17/25 8:00:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    CrowdStrike's Fal.Con 2026 Takes Over Mandalay Bay and Launches the Day Zero Threat Summit

    Record-breaking global demand propels CrowdStrike's flagship event to its biggest stage yet, uniting the world's defenders, innovators, and researchers at cybersecurity's premier conference CrowdStrike (NASDAQ:CRWD) today announced that Fal.Con 2026 will take over the Mandalay Bay Resort in Las Vegas from August 31 – September 3, 2026, and launch the inaugural Day Zero Threat Summit to kick off Fal.Con week – marking the next evolution of the cybersecurity industry's premier event. ​​Fueled by record-breaking demand following the sold out Fal.Con U.S. and Fal.Con Europe events in 2025, where more than 10,000 professionals from over 4,000 organizations attended in person, the expansion to

    11/7/25 8:00:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Financials

    Live finance-specific insights

    View All

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    - ECLIPSE 1 enrollment completed approximately two months ahead of schedule; ECLIPSE 2 and ECLIPSE 3 progressing with strong enrollment momentum, with topline data for all three studies expected in the first quarter of 2027 - Comprehensive data update for VIR-5500, a PSMA-targeting PRO-XTEN® dual-masked T-cell engager, planned for the first quarter of 2026 - First patient dosed in Phase 1 study of VIR-5500 in combination with androgen receptor pathway inhibitors (ARPIs) in first-line metastatic castration-resistant prostate cancer - Strong financial position and runway into mid-2027 with $810.7 million in cash and investments as of September 30, 2025 - Conference call scheduled for Nove

    11/5/25 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CrowdStrike Announces Date of Fiscal Third Quarter 2026 Financial Results Conference Call

    CrowdStrike Holdings, Inc. (NASDAQ:CRWD), today announced that it will release financial results for its fiscal third quarter 2026 ended October 31, 2025 after the U.S. market close on Tuesday, December 2, 2025. CrowdStrike will host a conference call that day at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) to discuss the results. To register for the live event please visit https://crowdstrike-fiscal-third-quarter-2026-results-conference-call.open-exchange.net/ A live webcast of the conference call and the financial results press release will be accessible from the CrowdStrike investor relations website at ir.crowdstrike.com. An audio webcast replay of the conference call will be avail

    11/5/25 8:30:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

    SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

    11/14/24 5:44:24 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

    SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

    11/14/24 5:40:50 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by CrowdStrike Holdings Inc.

    SC 13G/A - CrowdStrike Holdings, Inc. (0001535527) (Subject)

    11/14/24 1:22:38 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology